Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Leukemia, Biphenotypic, Acute 3Neutropenia 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Teratoma 1Solid Tumors 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 11Azacitidine 10fludarabine 9Whole-Body Irradiation 9Specimen Handling 9Biopsy 9Stem Cell Transplantation 8Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Tacrolimus 6Cytarabine 6X-Rays 5Hematopoietic Stem Cell Transplantation 5Decitabine 4Cyclosporine 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Magnetic Resonance Spectroscopy 3Injections 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Cyclosporins 3Busulfan 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3ruxolitinib 2pegylated granulocyte colony-stimulating factor 2olutasidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Chronic × pegylated granulocyte colony-stimulating factor × Clear all
NCT03670966 2026-05-04

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07046078 2026-01-30

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutchinson Cancer Center

Phase 2 Recruiting
20 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡